The problem of false-positive human papillomavirus DNA tests in cervical screening

Research output: Contribution to journalJournal article

Standard

The problem of false-positive human papillomavirus DNA tests in cervical screening. / Rebolj, Matejka; Pribac, Igor; Frederiksen, Maria Eiholm; Lynge, Elsebeth.

In: Current Pharmaceutical Design, Vol. 19, No. 8, 01.03.2013, p. 1439-49.

Research output: Contribution to journalJournal article

Harvard

Rebolj, M, Pribac, I, Frederiksen, ME & Lynge, E 2013, 'The problem of false-positive human papillomavirus DNA tests in cervical screening', Current Pharmaceutical Design, vol. 19, no. 8, pp. 1439-49. https://doi.org/10.2174/138161213804805595

APA

Rebolj, M., Pribac, I., Frederiksen, M. E., & Lynge, E. (2013). The problem of false-positive human papillomavirus DNA tests in cervical screening. Current Pharmaceutical Design, 19(8), 1439-49. https://doi.org/10.2174/138161213804805595

Vancouver

Rebolj M, Pribac I, Frederiksen ME, Lynge E. The problem of false-positive human papillomavirus DNA tests in cervical screening. Current Pharmaceutical Design. 2013 Mar 1;19(8):1439-49. https://doi.org/10.2174/138161213804805595

Author

Rebolj, Matejka ; Pribac, Igor ; Frederiksen, Maria Eiholm ; Lynge, Elsebeth. / The problem of false-positive human papillomavirus DNA tests in cervical screening. In: Current Pharmaceutical Design. 2013 ; Vol. 19, No. 8. pp. 1439-49.

Bibtex

@article{6566cefee52849babcd3dc57beac2ff8,
title = "The problem of false-positive human papillomavirus DNA tests in cervical screening",
abstract = "Human Papillomavirus (HPV) testing has been extensively studied in randomized controlled trials of primary cervical screening. Based on encouraging results concerning its high detection rates and a high negative predictive value for high-grade cervical intraepithelial neoplasia (CIN), HPV testing will probably replace cytology in future primary cervical screening. However, HPV testing is associated with more frequent false-positive tests compared to cytology. False-positive tests are defined as positive screening tests which are not subsequently confirmed with high-grade CIN. Several authors have claimed that the frequency of false-positive HPV tests could be reduced if an additional test was used to decide on referral for colposcopy of HPV-positive women. Data from the trials, however, do not support this claim. In fact, when compared to standard cytology screening and triage procedures, HPV testing leads to more screen-positive women being referred for colposcopy without having high-grade CIN, and to more women undergoing repeated testing. The only reasonable solution to the problem of false-positive tests appears to be a revised definition of a positive HPV screening test. However, further studies are needed to determine how this definition could be revised while at the same time keeping the high negative predictive value of HPV testing.",
author = "Matejka Rebolj and Igor Pribac and Frederiksen, {Maria Eiholm} and Elsebeth Lynge",
year = "2013",
month = "3",
day = "1",
doi = "10.2174/138161213804805595",
language = "English",
volume = "19",
pages = "1439--49",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers",
number = "8",

}

RIS

TY - JOUR

T1 - The problem of false-positive human papillomavirus DNA tests in cervical screening

AU - Rebolj, Matejka

AU - Pribac, Igor

AU - Frederiksen, Maria Eiholm

AU - Lynge, Elsebeth

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Human Papillomavirus (HPV) testing has been extensively studied in randomized controlled trials of primary cervical screening. Based on encouraging results concerning its high detection rates and a high negative predictive value for high-grade cervical intraepithelial neoplasia (CIN), HPV testing will probably replace cytology in future primary cervical screening. However, HPV testing is associated with more frequent false-positive tests compared to cytology. False-positive tests are defined as positive screening tests which are not subsequently confirmed with high-grade CIN. Several authors have claimed that the frequency of false-positive HPV tests could be reduced if an additional test was used to decide on referral for colposcopy of HPV-positive women. Data from the trials, however, do not support this claim. In fact, when compared to standard cytology screening and triage procedures, HPV testing leads to more screen-positive women being referred for colposcopy without having high-grade CIN, and to more women undergoing repeated testing. The only reasonable solution to the problem of false-positive tests appears to be a revised definition of a positive HPV screening test. However, further studies are needed to determine how this definition could be revised while at the same time keeping the high negative predictive value of HPV testing.

AB - Human Papillomavirus (HPV) testing has been extensively studied in randomized controlled trials of primary cervical screening. Based on encouraging results concerning its high detection rates and a high negative predictive value for high-grade cervical intraepithelial neoplasia (CIN), HPV testing will probably replace cytology in future primary cervical screening. However, HPV testing is associated with more frequent false-positive tests compared to cytology. False-positive tests are defined as positive screening tests which are not subsequently confirmed with high-grade CIN. Several authors have claimed that the frequency of false-positive HPV tests could be reduced if an additional test was used to decide on referral for colposcopy of HPV-positive women. Data from the trials, however, do not support this claim. In fact, when compared to standard cytology screening and triage procedures, HPV testing leads to more screen-positive women being referred for colposcopy without having high-grade CIN, and to more women undergoing repeated testing. The only reasonable solution to the problem of false-positive tests appears to be a revised definition of a positive HPV screening test. However, further studies are needed to determine how this definition could be revised while at the same time keeping the high negative predictive value of HPV testing.

U2 - 10.2174/138161213804805595

DO - 10.2174/138161213804805595

M3 - Journal article

C2 - 23016777

VL - 19

SP - 1439

EP - 1449

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 8

ER -

ID: 45261184